The Association of the British Pharmaceutical Industry (ABPI) is linking arms with the Academic Health Science Network in a five-year partnership that strives to accelerate uptake of transformative biomedical innovations by the NHS.
The groups intend to create a process whereby AHSNs and ABPI member companies can identify and collaborate on projects to fuel the spread of “proven innovation” in the health service.
These collaborative projects will address the new national priority areas of the 15 AHSNs, with digital and artificial intelligence, research, genomics and personalised medicine, and medicines optimisation among the list.
“As a result of this new partnership, patients will be able to benefit from the innovative medicines and technologies of the future faster and more consistently,” said ABPI chief executive Mike Thompson.
“The prize for success will be a virtuous circle that delivers benefits for patients and the NHS. There will also be economic benefits to the UK from a thriving life sciences ecosystem.”
AHSNs were set up by NHS England in 2013 to help spread innovation across the NHS.
